Antibacterial phage, phage peptides and methods of use thereof
Inventors
da Costa Garcia, Miguel Ângelo • Sousa de São José, Carlos Jorge • Rodrigues Leandro, Clara Isabel • Marçal Da Silva, Filipa Maria Rodrigues Pardal Dias Antunes • Martins Barbosa, Ana Raquel
Assignees
Technophage Investigacao e Desenvolvimento em Biotecnologia SA
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9737579-B2
Publication Date
2017-08-22
Expiration Date
Abstract
The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.
Core Innovation
The invention relates to methods of treating or reducing the incidence of infections caused by at least one of Staphylococcus aureus, Acinetobacter baumanni, Klebsiella pneumoniae, and Escherichia coli in a subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition containing a purified bacteriophage, where the bacteriophage has antibacterial activity against at least one of the listed bacteria and a genome with at least 99% sequence identity to selected SEQ ID NOs.
The disclosed bacteriophages include phage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, together with isolated phage-origin antibacterial polypeptides. The polypeptides include lysins/endolysins, CHAP domains, and tail proteins, and the disclosure frames coverage of isolated and purified forms and phage-related sequence identity concepts.
The document further describes optional use as single agents or in combination, including phage cocktails and co-administration concepts with antibiotics. In addition to therapeutic use, phage susceptibility concepts, anti-infective/disinfectant use, diagnostic methods, biosensor embodiments, and tail proteins in nanotechnology contexts, including as nanoscale conductors, are described.
Claims Coverage
The independent claim set includes one independent claim. It covers administering a pharmaceutical composition containing a purified bacteriophage defined by at least 99% genome sequence identity to specified SEQ ID NOs and by antibacterial activity against specified bacterial pathogens, for treating or reducing infection incidence.
Purified bacteriophage pharmaceutical composition defined by 99% genome sequence identity and antibacterial activity
A method comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a purified bacteriophage having a genome with at least 99% sequence identity to nucleotide sequences selected from SEQ ID NO:1074, SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:781, and having antibacterial activity against at least one of Staphylococcus aureus, Acinetobacter baumanni, Klebsiella pneumonia, and Escherichia coli.
Across the independent claim, inventive coverage centers on using a purified bacteriophage in a pharmaceutical composition, defined both by high genome sequence identity to specified SEQ ID NO nucleotide sequences and by antibacterial activity against the listed bacterial pathogens, for treating or reducing infection incidence in a subject.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?